$0.82
10.87%
Nasdaq, Oct 02, 04:00 pm EDT. Closed.
ISIN
US98973P1012
Symbol
TCRT

ZIOPHARM Oncology, Inc. Stock price

$0.82
-0.85 50.90% 1M
-2.11 72.01% 6M
-2.41 74.61% YTD
-1.81 68.82% 1Y
-18.56 95.77% 3Y
-266.18 99.69% 5Y
-840.68 99.90% 10Y
-771.68 99.89% 20Y
Nasdaq, Closing price Fri, Oct 02 2026
-0.10 10.87%
ISIN
US98973P1012
Symbol
TCRT
Industry

Is ZIOPHARM Oncology, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
$2.4m
Enterprise Value
$2.3m
Net debt
positive
Cash
$120.0k
Shares outstanding
2.5m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
negative | negative
P/B
3.7
Financial Health
Equity Ratio
72.6%
Return on Equity
-194.0%
ROCE
-614.9%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$930.0k | -
SBC as % of FCF
-
SBC Growth 1Y
126.8%
Share Count Growth 1Y
20.3%
Shareholder Yield
-20.3%
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
$-4.0m
EBIT
$-4.1m
Net Income
$-4.0m
Free Cash Flow | ex SBC
$-2.7m | $-3.7m
Growth
Revenue | estimate
-100.0% | -100.0%
EBITDA
0.2%
EBIT
-0.5%
Net Income
-0.5%
Free Cash Flow
4.2%
Margin
Gross
-
EBITDA
-134,466.7%
EBIT
-135,266.7%
Net
-133,666.7%
Free Cash Flow | ex SBC
-90,900.0% | -121,933.3%
More
EPS
$-1.6
FCF per Share
$-1.1
Short interest
0.3%
Employees
1
Rev per Employee
$10.0k

ZIOPHARM Oncology, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a ZIOPHARM Oncology, Inc. forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a ZIOPHARM Oncology, Inc. forecast:

Hold
50%
Sell
50%

Financial data from ZIOPHARM Oncology, Inc.

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 2.42 2.42
30% 30%
-
- Research and Development Expense 1.65 1.65
143% 143%
-
-4.03 -4.03
0% 0%
-
- Depreciation and Amortization 0.02 0.02
-
-
EBIT (Operating Income) EBIT -4.06 -4.06
1% 1%
-
Net Profit -4.01 -4.01
1% 1%
-

In millions USD.

Don't miss a Thing! We will send you all news about ZIOPHARM Oncology, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ZIOPHARM Oncology, Inc. Stock News

Neutral
GlobeNewsWire
●
15 days ago
Alaunos Therapeutics announces pricing of a public offering of common stock and pre-funded warrants to fund working capital and general corporate purposes.
Neutral
GlobeNewsWire
●
4 months ago
ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and improved liver health in diet-induced obese mice A non-confidential investor presentation summarizing the preclinical dataset is now available FORT LAUDERDALE, Fla., May 26, 2026 (GLOBE NEWSWIRE...
Neutral
GlobeNewsWire
●
5 months ago
FORT LAUDERDALE, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today announced updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies evaluating ALN1003, the Company's investigational oral metabolic therapeutic candidate.
More ZIOPHARM Oncology, Inc. News

Company Profile

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline include Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

Head office United States
CEO Mr. Weis
Employees 1
Founded 2003
Website alaunos.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today